Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Cheuk K. Lau is active.

Publication


Featured researches published by Cheuk K. Lau.


Bioorganic & Medicinal Chemistry Letters | 1996

FROM INDOMETHACIN TO A SELECTIVE COX-2 INHIBITOR Development of Indolalkanoic Acids as Potent and Selective Cyclooxygenase-2 Inhibitors

W.C. Black; Chris Bayly; Michel Belley; Chi-Chung Chan; S. Charleson; Danielle Denis; Jacques-Yves Gauthier; Robert Gordon; Daniel Guay; Stacia Kargman; Cheuk K. Lau; Yves Leblanc; Joseph A. Mancini; Marc Ouellet; David Percival; Patrick Roy; Kathryn Skorey; Philip Tagari; Philip J. Vickers; Elizabeth Wong; Lijing Xu; Petpiboon Prasit

Abstract A series of potent and highly selective cyclooxygenase-2 inhibitors have been prepared by replacing the benzoyl group of indomethacin with a 4-bromobenzyl group, and by extending the acetic acid side chain. These compounds show anti-inflammatory activity in rats with no evidence of GI toxicity, even at high doses.


Bioorganic & Medicinal Chemistry Letters | 2003

Pyridazinones as selective cyclooxygenase-2 inhibitors.

Chun Sing Li; Christine Brideau; Chi-Chung Chan; Chantal Savoie; David Claveau; S. Charleson; Robert Gordon; Gillian Greig; Jacques Yves Gauthier; Cheuk K. Lau; Denis Riendeau; Michel Therien; Elizabeth Wong; Petpiboon Prasit

Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.


Bioorganic & Medicinal Chemistry Letters | 1997

Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors

Michel Therien; Christine Brideau; Chi-Chung Chan; Wanda Cromlish; Jacques Yves Gauthier; Robert Gordon; Gillian Greig; Stacia Kargman; Cheuk K. Lau; Yves Leblanc; Chun-Sing Li; Gary P. O'Neill; Denis Riendeau; Patrick Roy; Zhaoyin Wang; Lijing Xu; Petpiboon Prasit

Abstract A series of 5,6-diarylimidazo[2.1-b]thiazole compounds were prepared and their inhibitory potencies against COX-2 and Cox-1 enzymes were measured. This led to the identification of L-766,112 as a potent, orally active and selective inhibitor of the COX-2 enzyme.


Bioorganic & Medicinal Chemistry Letters | 1997

A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

Patrick Roy; Yves Leblanc; Richard G. Ball; Christine Brideau; Chi-Chung Chan; Nathalie Chauret; Wanda Cromlish; Diane Ethier; Jacques-Yves Gauthier; Robert Gordon; Gillian Greig; Jocelyne Guay; Stacia Kargman; Cheuk K. Lau; Gary P. O'Neill; José M. Silva; Michel Therien; C. van Staden; Elizabeth Wong; Lijing Xu; Petpiboon Prasit

A series of 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles was prepared for evaluation of potency and selectivity against human COX-1 and COX-2 enzymes. This lead to the discovery of L-768,277, a potent and selective COX-2 inhibitor that also demonstrated good in vivo activity.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis and biological evaluation of 2,3-diarylthiophenes as selective cox-2 inhibitors. part II: Replacing the heterocycle

Jacques Yves Gauthier; Yves Leblanc; W. Cameron Black; Chi-Chung Chan; Wanda Cromlish; Robert Gordon; Brian P. Kennedey; Cheuk K. Lau; Serge Leger; Zhaoyin Wang; Diane Ethier; Jocelyne Guay; Joseph A. Mancini; Denis Riendeau; Philip Tagari; Philip J. Vickers; Elizabeth Wong; Lijing Xu; Peptiboon Prasit

Abstract The thiophene ring of DuP 697 was replaced by a variety of heterocycles and the products were tested for their ability to inhibit human Cox-2 and Cox-1, the isozymes of cyclooxygenase.


Bioorganic & Medicinal Chemistry Letters | 1996

SYNTHESIS AND BIOLOGICAL EVALUATION OF BOTH ENANTIOMERS OF L-761,000 AS INHIBITORS OF CYCLOOXYGENASE 1 AND 2

Yves Leblanc; W.C. Black; Chi-Chung Chan; S. Charleson; Daniel Delorme; Danielle Denis; Jacques-Yves Gauthier; Erich L. Grimm; Robert Gordon; Daniel Guay; Pierre Hamel; Stacia Kargman; Cheuk K. Lau; Joseph A. Mancini; Marc Ouellet; David Percival; Patrick Roy; Kathryn Skorey; Philip Tagari; Philip J. Vickers; Elizabeth Wong; Lijing Xu; Petpiboon Prasit

Abstract Both enantiomers of L-761,000 were prepared and evaluated for their cyclooxygenase activities.


Bioorganic & Medicinal Chemistry Letters | 2008

Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor

Yongxin Han; Michel Belley; Christopher I. Bayly; John Colucci; Claude Dufresne; André Giroux; Cheuk K. Lau; Yves Leblanc; Daniel J. McKay; Michel Therien; Marie-Claire Wilson; Kathryn Skorey; Chi-Chung Chan; Giovana Scapin; Brian P. Kennedy

A series of quinoline/naphthalene-difluoromethylphosphonates were prepared and were found to be potent PTP1B inhibitors. Most of these compounds bearing polar functionalities or large lipophilic residues did not show appreciable oral bioavailability in rodents while small and less polar analogs displayed moderate to good oral bioavailability. The title compound was found to have the best overall potency and pharmacokinetic profile and was found to be efficacious in animal models of diabetes and cancer.


Journal of Biological Chemistry | 2006

Conformation-assisted Inhibition of Protein-tyrosine Phosphatase-1B Elicits Inhibitor Selectivity over T-cell Protein-tyrosine Phosphatase

Ernest Asante-Appiah; Sangita B. Patel; Caroline Desponts; Jillian Taylor; Cheuk K. Lau; Claude Dufresne; Michel Therien; Rick Friesen; Joseph W. Becker; Yves Leblanc; Brian Kennedy; Giovanna Scapin

PTP-1B represents an attractive target for the treatment of type 2 diabetes and obesity. Given the role that protein phosphatases play in the regulation of many biologically relevant processes, inhibitors against PTP-1B must be not only potent, but also selective. It has been extremely difficult to synthesize inhibitors that are selective over the highly homologous TCPTP. We have successfully exploited the conservative Leu119 to Val substitution between the two enzymes to synthesize a PTP-1B inhibitor that is an order of magnitude more selective over TCPTP. Structural analyses of PTP-1B/inhibitor complexes show a conformation-assisted inhibition mechanism as the basis for selectivity. Such an inhibitory mechanism may be applicable to other homologous enzymes.


Tetrahedron | 1996

Syntheses of quinolines, dihydro- and tetrahydroquinolines via ortho-quinone methide imine intermediate

Jennifer M. Wiebe; Alain S. Caillé; Laird A. Trimble; Cheuk K. Lau

Abstract A general process for ortho -specific hydroxyalkylation of secondary anilines via N-alkylanilinochlorophenylboranes has been developed. Pyrolysis of the resulting ortho -aminobenzyl alcohols generated the corresponding ortho -quinone methide imines, which can participate in an electrocyclic reaction to yield 2-substituted-1,2-dihydroquinolines. The resulting dihydroquinolines can be converted readily to a variety of 2-substituted quinolines. Intramolecular trapping of the ortho -quinone methide imines with an olefin via a [2+4] cycloaddition reaction leads to the syntheses of various polycyclic tetrahydroquinolines.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors

Cheuk K. Lau; Christine Brideau; Chi-Chung Chan; S. Charleson; Wanda Cromlish; Diane Ethier; Jacques Yves Gauthier; Robert Gordon; Jocelyne Guay; Stacia Kargman; Chun-Sing Li; Petpiboon Prasit; Denis Reindeau; Michel Therien; Denise M. Visco; Lijing Xu

A series of 3-heteroaryloxy4-phenyl-2-5H)-furanones were prepared and evaluated for their potency and selectivity as COX-2 inhibitors. This led to the identification of L-778,736 as a potent, orally active and selective inhibitor of the COX-2 enzyme.

Collaboration


Dive into the Cheuk K. Lau's collaboration.

Researchain Logo
Decentralizing Knowledge